We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
Comfort Systems
FIX
$53.5B
| $2.07M | ﹤0.01% |
+2,214
| New | +$2.04M |
|
777
J.M. Smucker
SJM
$13.5B
| $2.06M | ﹤0.01% |
21,073
+2,257
| +12% | +$233K |
|
|
NBIS
778
Nebius Group N.V.
NBIS
$37.6B
| $2.04M | ﹤0.01% |
24,325
-28,763
| -54% | -$2.98M |
|
779
Cousins Properties
CUZ
$5.31B
| $2.02M | ﹤0.01% |
78,255
+7,332
| +10% | +$191K |
|
780
Kite Realty
KRG
$5.86B
| $2M | ﹤0.01% |
83,260
+3,508
| +4% | +$79.6K |
|
781
Shattuck Labs
STTK
$646M
| $1.94M | ﹤0.01% |
531,177
+436,673
| +462% | +$1.04M |
|
782
iShares MSCI Ireland ETF
EIRL
$75.5M
| $1.94M | ﹤0.01% |
26,357
-200
| -0.8% | -$14K |
|
783
Trip.com Group
TCOM
$29B
| $1.93M | ﹤0.01% |
26,819
| – | – |
|
784
Full Truck Alliance
YMM
$10B
| $1.85M | ﹤0.01% |
172,854
+626
| +0.4% | +$7.51K |
|
785
Stanley Black & Decker
SWK
$14.5B
| $1.84M | ﹤0.01% |
24,704
-3,873
| -14% | -$273K |
|
|
SNDK
786
Sandisk
SNDK
$150B
| $1.8M | ﹤0.01% |
+7,574
| New | +$1.52M |
|
787
TScan Therapeutics
TCRX
$48.5M
| $1.79M | ﹤0.01% |
1,785,241
+430,421
| +32% | +$623K |
|
788
Biodesix
BDSX
$211M
| $1.78M | ﹤0.01% |
+262,425
| New | +$1.93M |
|
789
Macerich
MAC
$7.4B
| $1.77M | ﹤0.01% |
95,950
+6,246
| +7% | +$110K |
|
790
Interactive Brokers
IBKR
$38.4B
| $1.77M | ﹤0.01% |
27,526
-772
| -3% | -$51.7K |
|
791
Fomento Económico Mexicano
FMX
$41.2B
| $1.76M | ﹤0.01% |
17,438
-34,697
| -67% | -$3.37M |
|
|
NVMI
792
Nova
NVMI
$11.7B
| $1.75M | ﹤0.01% |
5,325
-2,303
| -30% | -$740K |
|
793
iShares MSCI Saudi Arabia ETF
KSA
$612M
| $1.74M | ﹤0.01% |
47,739
| – | – |
|
794
Hasbro
HAS
$13.5B
| $1.74M | ﹤0.01% |
21,174
-1,987
| -9% | -$156K |
|
|
DHC
795
Diversified Healthcare Trust
DHC
$2.15B
| $1.73M | ﹤0.01% |
357,720
| – | – |
|
796
Avalo Therapeutics
AVTX
$1.01B
| $1.73M | ﹤0.01% |
95,426
+22,626
| +31% | +$382K |
|
797
American Financial Group
AFG
$11.9B
| $1.72M | ﹤0.01% |
12,618
+1,845
| +17% | +$253K |
|
798
Invesco
IVZ
$12.4B
| $1.71M | ﹤0.01% |
64,983
+11,477
| +21% | +$280K |
|
799
Reddit
RDDT
$34.3B
| $1.69M | ﹤0.01% |
7,360
+2,801
| +61% | +$589K |
|
800
Zurn Elkay Water Solutions
ZWS
$8.55B
| $1.61M | ﹤0.01% |
34,634
| – | – |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.